Xeljanz (tofacitinib) 4.67/5 (3)

Share Button

This page contains a brief description that does not cover the medication. For more information read the review in Felleskatalogen.no for the respective drug.


Tofacitinib belongs to the drug group JAK inhibitors. JAK inhibitors are a relatively new group of disease-suppressing drugs in the form of tablets for rheumatoid arthritis or active psoriatic arthritis in adults. They reduce rheumatic inflammation and the immune system by inhibiting the janus kinase enzymes JAK1, JAK2, JAK3 and to a lesser extent TyK2. This weakens the interleukins (IL-2, -4, -6, -7, -9, -15, -21) and interferon I and II.

  • Tofacitini (Xeljans) tablets are usually dosed 5mg twice daily
  • Baricitnib (Aluminum tablets are dosed 4mg once daily)

Xeljanz (tofacitinib) is a tablet to Rheumatoid arthritis (RA) og psoriatic arthritis when there is insufficient effect of methotrexate or similar anti-rheumatic drug alone. Xeljanz works by blocking Janus Kinase (JAK) signals in the cells. This reduces the development of rheumatic inflammation.

The treatment

It is usually combined with methotrexate

  • The usual dose is 1mg (5mg) morning and evening but lower dose in some cases
  • Has also shown effect at Psoriatic arthritis, Psoriasis in the skin and Ulcerative colitis (a chronic intestinal inflammation)
  • Possible side effects include illness Herpes zoster ( "Shingles"),  Tuberculosis, others Opportunistic infections and generally increased risk of infection
  • High doses (10mg x 2 or more) increase the risk of blood clots in the lungs (pulmonary embolism) and should not be used in vulnerable people (birth control pills, smoking, obesity, hereditary tendency to thrombosis, cancer, heart failure or prolonged bed rest)
  • People over the age of 65 should only be treated with tofacitinib if other medicinal products are not appropriate. This is due to increased risk of serious infections
  • Treatment should be stopped before major scheduled surgical procedures
  • Tofacitinib should not be used during pregnancy or breast-feeding
  • Before starting treatment, it is recommended to exclude signs of


Follow-up during treatment

This page has had 1 visits today

Please rate this page